Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

May 20, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

February 1, 2025

Conditions

Breast Cancer

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER